Analyst Expectations for Autolus Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Autolus Therapeutics (NASDAQ:AUTL) has received 4 analyst ratings in the last quarter, with 3 being bullish and 1 indifferent. The 12-month price target average for AUTL is $7.2, a significant increase from the previous $3.20 target, indicating a positive shift in analyst sentiment. Analysts consider company financials, meetings, and insider communications to provide these ratings, which are updated quarterly or after major company events.
December 13, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Autolus Therapeutics has seen a positive shift in analyst ratings with an average 12-month price target of $7.2, reflecting a 125% increase from the previous target.
The increase in the average price target for AUTL suggests that analysts have a more optimistic view of the company's future performance. This could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100